Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.
about
Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient dataMathematical Modelling to Guide Drug Development for Malaria EliminationPlasmodium falciparum drug resistance in AngolaAntimalarial drug resistance in Africa: key lessons for the futureArtemisinin Action and Resistance in Plasmodium falciparumMolecular Mechanisms for Drug Hypersensitivity Induced by the Malaria Parasite's Chloroquine Resistance TransporterPast and new challenges for malaria control and elimination: the role of operational research for innovation in designing interventionsPfCRT and PfMDR1 modulate interactions of artemisinin derivatives and ion channel blockersDrug resistance in eukaryotic microorganisms.A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug PiperaquineThe clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread.Molecular markers of anti-malarial drug resistance in Central, West and East African children with severe malaria.Host candidate gene polymorphisms and associated clearance of P. falciparum amodiaquine and fansidar resistance mutants in children less than 5 years in Cameroon.Prevalence of Plasmodium falciparum anti-malarial resistance-associated polymorphisms in pfcrt, pfmdr1 and pfnhe1 in Muheza, Tanzania, prior to introduction of artemisinin combination therapy.Diversity-oriented synthesis and activity evaluation of substituted bicyclic lactams as anti-malarial against Plasmodium falciparumThe effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data.Maximizing antimalarial efficacy and the importance of dosing strategies.Slow Clearance of Plasmodium falciparum in Severe Pediatric Malaria, Uganda, 2011-2013.Molecular markers of anti-malarial drug resistance in southwest Ethiopia over time: regional surveillance from 2006 to 2013.Temporal trends in prevalence of Plasmodium falciparum molecular markers selected for by artemether-lumefantrine treatment in pre-ACT and post-ACT parasites in western Kenya.Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso.Prevalence of K13-propeller gene polymorphisms among Plasmodium falciparum parasites isolated from adult symptomatic patients in northern Uganda.Significant geographical differences in prevalence of mutations associated with Plasmodium falciparum and Plasmodium vivax drug resistance in two regions from Papua New GuineaArtesunate treatment of severe pediatric malaria: A review of parasite clearance kinetics and clinical implications.In Vitro and Molecular Surveillance for Antimalarial Drug Resistance in Plasmodium falciparum Parasites in Western Kenya Reveals Sustained Artemisinin Sensitivity and Increased Chloroquine SensitivityAssessment of pharmacokinetic compatibility of short acting CDRI candidate trioxane derivative, 99-411, with long acting prescription antimalarials, lumefantrine and piperaquine.An outbreak of artemisinin resistant falciparum malaria in Eastern Thailand.Evaluation of artemether-lumefantrine efficacy in the treatment of uncomplicated malaria and its association with pfmdr1, pfatpase6 and K13-propeller polymorphisms in Luanda, AngolaPooled Amplicon Deep Sequencing of Candidate Plasmodium falciparum Transmission-Blocking Vaccine Antigens.Combinatorial Genetic Modeling of pfcrt-Mediated Drug Resistance Evolution in Plasmodium falciparum.Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies.A Method for Amplicon Deep Sequencing of Drug Resistance Genes in Plasmodium falciparum Clinical Isolates from India.Artemisinin-Resistant Plasmodium falciparum Malaria.Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai-Myanmar Border (2003-2013): The Role of Parasite Genetic Factors.Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia.Analysis of anti-malarial resistance markers in pfmdr1 and pfcrt across Southeast Asia in the Tracking Resistance to Artemisinin Collaboration.Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether-lumefantrine treatment in Mali.The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine.Molecular Profile of Malaria Drug Resistance Markers of Plasmodium falciparum in Suriname.pfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies.
P2860
Q26783646-9E87C438-82F8-4619-8F0F-7531E5084B48Q28067367-B0594FF5-5FE1-4E44-9DB4-F92A0ABE8583Q28075079-B18A145A-EA73-4231-9555-7B38ADFA4A3EQ28081457-EA0CBB2F-0751-4CB5-B8BB-FC11FC4D3C56Q28276294-62568A64-2FCF-49C1-AAC5-6998DC65AAC3Q28552775-E0B137B9-2DB4-4737-A14F-9799F95FD17CQ28646971-63D7AF52-AA72-4F4D-B196-74C90CF6E9E3Q28833540-A085508F-AF27-4E95-A7BF-876F014A9AF5Q30248243-74C6E1C5-836C-45B5-B438-909271F7A34DQ33654512-2873FE97-3BDD-4EE2-8DB5-136713ED805AQ33655603-36ACF40B-DE1D-4B47-856B-95EC4F20A9E1Q33721915-EEADCC6E-1C26-49FA-B1EC-4F3105B78222Q34562743-019ADADB-7649-45DD-A786-742366DC063FQ35356543-9EC53CE6-987A-40EB-88CC-517660649152Q35457856-4A68479D-9D12-4D62-B3A6-B6AF24EB89E6Q35580908-13032D5A-D9E4-4EDD-A2E7-F834593F17BFQ35588265-355601C8-8DC6-4DBF-9AFE-BDB5C6478B1EQ35780311-A57B9220-CC88-45B9-AB6E-214371172E01Q35814367-41C6A1A5-350E-4B39-AA93-684F0AE29667Q35849636-92C8C335-B73B-4423-A683-A12CA5893451Q35975011-09FA4B37-1E01-44CA-AD22-4BECFB4BAB53Q36108352-23B5AA18-C2EE-4F3E-9BB4-67052A5D3240Q36144097-DECA3103-BC80-4ACE-A943-56B5CAB0D5BBQ36277347-5D95730E-2254-4E05-93AD-A5623D6E73EDQ36290734-E6396FD0-67AA-4351-989C-33B24A362CE3Q36316695-9C664EF6-663F-405D-8BFF-08CBD3E489BFQ36330431-3875BA1F-1426-4DAA-A805-0348CF9E1638Q36376796-6C0B366F-1F7B-42D0-A2B2-560AF841A2CCQ36455757-64823C95-B0C1-43B8-9632-0FD4087D22F0Q36904205-D135135E-C54D-4793-9237-B839D27A8BF9Q36919648-80F3E30D-6301-4228-A376-BC7E4E24943EQ36933131-DEF1C074-9530-40DD-9010-8D5B168E9C58Q37193474-004EF4C2-4035-40BC-8BE0-0BEF02E46F3FQ37200509-B4C0CE03-4795-423A-A2E6-DF6C68D522A6Q37233322-7A8364F4-725E-4BBF-9C93-94D2D4D86B9EQ37402952-82F3BCB5-7186-47BB-AEEE-8992C8EBC862Q37621092-83C05ABE-83F9-4D6A-8621-7EF4068ABEDBQ38529669-72A27476-4994-4391-BE3E-018A08C46CDBQ38822049-A8126951-13A3-4D69-A855-C26A454FF5EFQ39206934-82209B98-08D8-42F3-9C3D-626032F16852
P2860
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Polymorphisms in Plasmodium fa ...... ne and artesunate-amodiaquine.
@ast
Polymorphisms in Plasmodium fa ...... ne and artesunate-amodiaquine.
@en
Polymorphisms in Plasmodium fa ...... ne and artesunate-amodiaquine.
@nl
type
label
Polymorphisms in Plasmodium fa ...... ne and artesunate-amodiaquine.
@ast
Polymorphisms in Plasmodium fa ...... ne and artesunate-amodiaquine.
@en
Polymorphisms in Plasmodium fa ...... ne and artesunate-amodiaquine.
@nl
prefLabel
Polymorphisms in Plasmodium fa ...... ne and artesunate-amodiaquine.
@ast
Polymorphisms in Plasmodium fa ...... ne and artesunate-amodiaquine.
@en
Polymorphisms in Plasmodium fa ...... ne and artesunate-amodiaquine.
@nl
P2093
P2860
P50
P921
P356
P1476
Polymorphisms in Plasmodium fa ...... ne and artesunate-amodiaquine.
@en
P2093
A Fabrice Somé
ASAQ Molecular Marker Study Group
Ahmed Zeynudin
Alexis Nzila
Anastasia Grivoyannis
Andreas Mårtensson
Badria B El-Sayed
Billy Ngasala
Birgit Schramm
Carol Hopkins Sibley
P2860
P304
P356
10.4269/AJTMH.14-0031
P407
P50
P577
2014-07-21T00:00:00Z